The CEO of the country’s largest for-profit, publicly traded health system is bullish on healthcare AI. 

Discussions of AI governance may cause many an eye to glass over, but the discipline is as crucial to the ascent of AI in healthcare as big training datasets drawn from diverse patient populations.

Treating AMI patients with colchicine is not associated with better cardiovascular outcomes, according to new data presented at TCT. The drug did help with inflammation, but that was the only benefit researchers could identify.

Another MAC has agreed to cover the use of these advanced technologies to evaluate patients for signs of coronary artery disease. 

Medtronic is now the first company to offer two FDA-approved PFA systems for the treatment of persistent AFib. The company’s PulseSelect PFA system gained approval in December 2023. 

Payers are still running ahead of providers in the AI arms race. 

For whatever reason, the grownups seem to get all the attention when talk turns to AI in healthcare. All the kiddos get to do is look on and listen in. Now comes a worthy little effort to balance the seesaw.

Many Americans have never heard of peripheral artery disease or other common vascular conditions. In fact, a vast majority are not sure what vascular surgeons do.